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I rritable bowel syndrome (IBS) pain, diarrhea, or constipation result from one or more pathophysiologic mechanisms in each individual patient. The treatment of IBS typically addresses the predominant symptom experienced by the patient and targets the pathophysiology, such as accelerated transit or visceral hypersensitivity. There are still no effective disease-modifying treatments 1 ; however, research that has demonstrated and validated biomarkers based on the pathophysiology of IBS provides opportunities to direct effective treatments to correct those mechanisms, such as abnormalities of colonic transit or increased colonic concentrations of bile acids. 2, 3 Novel therapeutic approaches that have targeted these abnormalities in singlecenter, randomized controlled trials (RCTs) using biomarker end points have correctly predicted therapeutic efficacy based on symptom-based end points in phase 2B or 3 multicenter RCTs. 3 Visceral pain is a hallmark of IBS. Pain is transmitted to conscious perception in the brain via a 3-neuron chain, as with somatic pain; the main pathways are vagal, thoracolumbar, and lumbosacral afferents that have both pronociceptive and antinociceptive ion channels and receptors. 4 There are several relevant neurotransmitters on the afferents conveying sensory signals to the central nervous system, including serotonin (5-hydroxytryptamine ) and neurokinins, as well as ion channels including transient receptor potential (TRP) channels that mediate activation of afferent nerves and detect thermal and chemical stimuli that produce acute or persistent pain. 5 This article addresses the current approaches to treatment of IBS, including lifestyle modifications, changes in diet, alternative and herbal therapies, probiotics, and pharmacotherapy ( Figure) 6 directed to the motility, sensation, and intraluminal milieu of patients with IBS. There are recent national society guidelines for the management of IBS based on the available literature and systematic reviews and meta-analyses. [7] [8] [9] [10] With recently introduced medications, trials have used US Food and Drug Administration (FDA)erecommended end points to judge efficacy. The level of evidence is weaker for more traditional therapies that were previously approved on the basis of smaller, lower-quality RCTs that 11 For each intervention discussed, the mechanisms, efficacy, and safety (when available) are summarized.
GENERAL LIFESTYLE MEASURES

Dietary Modifications
Many patients believe that their IBS symptoms are due to food sensitivity. 12 Mechanisms. Food generates symptoms in patients with IBS, 13 and 4 potential explanations are (1) prominent contractile 14 and sensory 15 responses of the colon to the ingestion of food ("gastrocolonic response"); (2) alterations in the microbiome (which may occur quite rapidly after a change in diet) 16 ; (3) insoluble dietary fiber may exacerbate IBS symptoms 17 ; and (4) dietary antigens may alter the intestinal epithelial barrier. 18 These putative mechanisms provide rationale for dietary modifications.
Efficacy. The quality of published trials of dietary interventions in IBS is generally weak. A systematic review recommended that more evidence is needed. 19 Specific diets, including a diet low in fructose, oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAPs), are discussed subsequently.
Elimination Diets
A sham diet RCT of 150 patients assessed a diet based on avoidance of foods to which patients had 3-fold elevated IgG antibody titers over background. 20 Symptoms were substantially improved at 12 weeks. The results of the study revealed that the number needed to treat (NNT) was 9, and reintroducing eliminated foods resulted in substantial worsening of symptoms. It is unclear whether the diet's efficacy differed according to stool pattern. Conversely, double-blind rechallenge to the dietary triggers resulted in reproducible symptoms in only approximately 25% of patients. 21 Increased Dietary Fiber Efficacy. In the largest trial of the use of fiber in patients with IBS (all subtypes) in the primary care setting, 275 patients were randomized to 12 weeks of treatment with soluble fiber (psyllium), insoluble bran fiber, or placebo. 22 Whereas bran was of no benefit, there was reduction in IBS symptom severity score (IBS-SSS) with psyllium over placebo at 12 weeks and a greater proportion of responders (>2 weeks' adequate relief per month), with an NNT for psyllium of 4. Adverse event rates (overall) were not significantly more prevalent in either of the fiber groups compared with placebo.
In a systematic review and meta-analysis 23 that included 906 patients with IBS in 14 RCTs (most of low methodological quality), there was only modest improvement of symptoms with fiber (NNT of 10), and the beneficial effect was limited to psyllium (which was tested in 499 patients in 7 studies) with an NNT of 7. The effect of bran was not significant. The rates of adverse events with psyllium, bran, and placebo were not significantly different. In contrast to weak benefits in IBS, mixed soluble and insoluble fiber and psyllium were equally efficacious in improving constipation in patients with chronic constipation. 24 Mechanism. The mechanism of benefit with psyllium is uncertain and is unlikely to relate to stool bulking alone because bran has similar effects. 25 Conversely, increased production of short-chain fatty acids, such as butyrate, with psyllium treatment may have antiinflammatory effects on the colonic mucosa 26 or alter the intestinal microbiota, 27 which may conceivably contribute to reported benefits of psyllium.
Low FODMAP Diet Mechanism. FODMAPs are present in many commonly consumed foods (such as stone fruits and legumes), lactose-containing foods, and artificial sweeteners. Because these chemical substances are poorly absorbed, they may induce osmotic effects (and fluid secretion) or fermentation (and distention) in the intestine, 28, 29 leading to increased colonic sensitivity from the distention. 30 Sugar alcohols can induce dose-dependent symptoms of flatulence, abdominal discomfort, and laxative effects when consumed by both healthy volunteers and patients with IBS. 31 A low FODMAP diet may lead to reduction in bacterial abundance 32 and lower proportions of certain bacteria including Bifidobacterium. 33 However, it is unclear whether the restriction of FODMAPs leads to long-term effects on the gut microbiota.
Efficacy. The clinical benefits of a low FODMAPs diet remain indeterminate. For example, a crossover RCT comparing a diet low in FODMAPs with a typical Australian diet in 30 patients with IBS of all subtypes 34 reported reduced global IBS symptoms, bloating, and pain with the low FODMAP diet, with greater benefit in those with diarrheapredominant IBS (IBS-D). Conversely, a larger parallel-group RCT of 67 patients with IBS found no difference in efficacy between a low FODMAPs diet and conventional dietary recommendations, 35 with both diets producing benefit relative to baseline.
Several meta-analyses suggest efficacy of a low FODMAPs diet 36, 37 ; however, analysis identified risk of bias, primarily due to lack of proper blinding and choice of control. 38 Despite the weak evidence, the National Institute for Health and Care Excellence of the United Kingdom recommended as a first-line treatment the use of a low FODMAPs diet for patients with IBS in primary care. 39 The IBS dietary algorithm from the British Dietetic Association was simplified to first-line healthy eating (provided by any health care professional) and second-line low FODMAP dietary advice. 40 
Gluten-Free Diet
In the absence of markers of celiac disease, there is evidence that a subgroup of patients with IBS may benefit from use of a glutenfree diet (GFD).
Mechanism. The mechanism of the effect of gluten in IBS is unclear; a gluten-containing diet affects small bowel epithelial messenger RNA expression of barrier protein and higher small bowel mucosal permeability in patients with IBS-D compared with a GFD. 41 There is also evidence that there are differences in expression of immune markers on gluten sensitivity without celiac disease in those who present with symptoms mimicking IBS-D and increased expression of toll-like receptor 2 and reduced regulatory T-cell marker FOXP3 relative to controls and patients with celiac disease. 42 Because wheat contains high levels of fructans in addition to gluten, a trial examined the combination of a low FODMAPs diet and a GFD 43 and found no additive effect of the GFD, suggesting that reduction in fructans may partly explain the effectiveness of a GFD in IBS.
Efficacy. Two RCTs reported that response to a GFD is greater in patients who are HLADQ2e or HLA-DQ8epositive. 41, 44 A third RCT found similar improvement in IBS-SSS; in addition, patients who were HLA-DQ2e or HLA-DQ8epositive had a greater reduction in depression score and increase in vitality score on the GFD, whereas patients who were HLA-DQ2enegative had improved bloating scores. 45 Exercise A few studies have examined exercise as an approach to reduce symptoms in IBS. In a Swedish trial, initially over 12 weeks 46 and subsequently with median follow-up of 5.2 years (range, 3.8-6.2 years), 47 20 to 60 minutes of moderate to vigorous physical activity (most commonly walking, aerobics, and cycling) on 3 to 5 days per week was associated with significant improvement in symptom scores (IBS-SSS and psychological symptoms) over the control arm. It is unclear whether the effect of exercise differs according to IBS subtype.
Other movement-based, self-regulatory behavioral treatments have been reported to be beneficial for patients with IBS, with yoga tending to reduce the severity of IBS and somatic symptoms and walking improving overall gastrointestinal tract symptoms, negative affect, and anxiety. 48 
ALTERNATIVE AND HERBAL THERAPIES Prebiotics and Probiotics
Prebiotics include food ingredients such as fructo-oligosaccharides or inulin that remain undigested in the human gastrointestinal system and can promote the growth or activity of gut bacteria. In contrast, probiotics are live or attenuated microorganisms that can affect the composition of the intestinal microorganisms. Probiotics may have anti-inflammatory and antinociceptive properties. [49] [50] [51] [52] Two trials of prebiotics in IBS were reported in the past 3 years. An RCT of 12 weeks' duration compared 6-g partially hydrolyzed guar gum, a prebiotic fiber, to placebo in 121 patients with IBS of all subtypes 53 and found significant improvement in bloating; however, there was no benefit on global symptoms, abdominal pain, or quality of life. A second study tested the prebiotic inulin (900 mg) in children with IBS, and none of the 6 symptoms of IBS tested improved, in contrast to significant improvements with synbiotic treatment (5Â10 9 colony-forming units [CFU] of Bifidobacterium lactis B94 and 900 mg of inulin) and probiotic treatment (5Â10 9 CFU of B lactis B94) tested over 4 weeks. 54 In a meta-analysis published in 2014, 35 trials of probiotics involving 3452 patients with IBS 55 found that probiotics have a beneficial overall effect in IBS (NNT of 7) with the greatest impact on abdominal pain, bloating, and flatulence but not on bowel urgency or bowel function. Mild adverse events were significantly more common with probiotics compared with placebo.
More recent meta-analyses of probiotics suggest benefit for overall symptoms in patients with IBS treated with Bifidobacterium infantis (5 RCTs), 56 Saccharomyces cerevisiae CNCM I-3856 (2 trials), 57 and single probiotics at relatively lower dosage of organisms (<10 10 CFU/d) and shorter duration (<8weeks). 58 A meta-analysis of 15 trials that included 1793 patients reported improvement of general symptoms (7 trials) and of pain, distention, bloating, and flatulence in 2 to 3 trials each. 59 With most trials of probiotics, few were of high methodological quality, and combining data from different probiotic species, strains, or combinations may not be valid. 60 Other Herbal Therapies The efficacy of other herbal therapies in IBS is unclear. Iberogast is a mixture of diverse extracts of flower, leaves, fruit, root, and herbs 61 with antispasmodic effects on gastrointestinal smooth muscle 62 through diverse mechanisms 63 and secretory effect on diverse chloride channels. 64 In an RCT of 208 patients with IBS, 65 there was improvement in global symptoms and abdominal pain scores with Iberogast compared with placebo.
The benefits of Chinese herbal medicines in IBS are inconsistent. [66] [67] [68] MEDICATIONS FOR PAIN Numerous pharmacological agents for treatment of IBS are currently available, with varying modes of action, efficacy, quality of data, and adverse events (Table) .
Antispasmodic Drugs
Mechanism. Antispasmodics inhibit the action of acetylcholine at muscarinic or tachykinin NK 2 receptors or block calcium channels on gastrointestinal smooth muscle and alter gastrointestinal transit, contributing to relief of pain and disturbances in bowel habit.
Efficacy. Systematic reviews have documented weak evidence for the benefit of some antispasmodics for abdominal pain and global symptom relief, 69 and significant improvement in abdominal pain in 7 of 9 studies, bowel symptoms in 2 of 9, and global symptom severity in 4 of 9 studies was reported. 70 In a meta-analysis of 22 separate RCTs involving 1778 patients and 12 different antispasmodic drugs, 71 antispasmodics were more effective than placebo, with an NNT of 5 overall and slightly lower NNTs with hyoscine (NNT, 3.5) (426 patients enrolled in 3 trials), otilonium (NNT, 4.5) (435 patients enrolled in 4 trials,), cimetropium (NNT, 3) (158 patients enrolled in 3 trials), and pinaverium (NNT, 3) (188 patients enrolled in 3 trials), but confidence in these estimates is reduced because of significant heterogeneity, methodological weaknesses, possible publication bias, and insufficient information on efficacy according to IBS subtype. In addition, most of the drugs studied are not approved by the FDA for the treatment of IBS in the United States, and promising data for those medications are reviewed elsewhere. 6 Safety. Antispasmodics cause more adverse effects than placebo, with the most common being dry mouth, dizziness, blurred vision, and constipation.
Peppermint Oil
Mechanism. The major constituent of peppermint oil is menthol, which inhibits smooth muscle contractility in the gastrointestinal tract by blocking calcium influx. 72, 73 Menthol also induces analgesia by activating the temperature-sensing ion channel, TRP cation channel subfamily M member 8, 74 which has antinociceptive properties in visceral afferents.
Efficacy. Peppermint oil was more effective than placebo in a meta-analysis of 4 trials including 392 patients with IBS (NNT of 2.5). 71 The same methodological issues described for antispasmodics apply, and the estimate of efficacy (NNT) is likely inaccurate.
In a later meta-analysis of 5 RCTs of peppermint oil including 197 patients receiving active treatment and 195 receiving placebo, peppermint oil resulted in global improvement of IBS symptoms (5 studies) and abdominal pain (5 studies). 75 A novel formulation with sustained release in the small intestine 76 was tested in a 4-week trial in 72 patients with IBS-D or IBS with mixed symptoms, and there was no superiority over placebo for total IBS symptom score, although both treatment arms produced improvement from baseline.
Safety. Peppermint oil can cause symptoms of gastroesophageal reflux, xerostomia, belching, a peppermint taste in the mouth, and a peppermint smell. Antidepressants Mechanism. The rationale for using antidepressants in IBS includes the coexistence of psychological disorders in IBS, 77 evidence that depression modifies the central nervous system response to painful stimuli, 78 the benefits of antidepressants in chronic painful disorders, 79, 80 and correction of altered intestinal transit. Thus, tricyclic antidepressants (TCAs) prolong orocecal and intestinal transit times, whereas selective serotonin reuptake inhibitors (SSRIs) decrease orocecal transit time. 81 Based on this difference, TCAs are used in IBS-D and SSRIs are preferred in constipation-predominant IBS (IBS-C).
The mechanism of action of antidepressants in IBS is multifactorial and may include reduced activation of pain centers in the anterior cingulate cortex and central pain processing 82 and peripheral mechanisms that have an effect on pain sensation such as colonic compliance and visceral afferent function.
Efficacy. An updated systematic review and meta-analysis 83 including 17 separate trials of antidepressants found overall beneficial effects of antidepressants on IBS symptoms (NNT of 4). However, low level of trial quality, inconsistencies of trial end points, questionable generalizability, uncharacteristic response levels of the placebo arm (14%) 84 or the antidepressant (63%), 85 and evidence of heterogeneity between studies and possible publication bias raise questions about the accuracy of the reported NNT.
In general, TCAs appear to have greater efficacy with an NNT of 4. In the metaanalysis, no heterogeneity was seen between the 11 studies that included TCAs compared with SSRIs, which also had an NNT of 4 but with significant heterogeneity among 7 trials. Seven RCTs reported benefit for abdominal pain, but there was substantial heterogeneity between studies. Effectiveness according to IBS subtype has been studied in only 2 RCTs. 84, 85 Three trials of antidepressants in IBS have found no correlation between improvement in IBS symptoms and depression scores, [86] [87] [88] and a fourth trial of a TCA revealed greater benefit in nondepressed individuals. 89 Three open-label trials have studied the effects of duloxetine, a serotoninnorepinephrine reuptake inhibitor (SNRI) that has had efficacy in the treatment of IBS, such as in IBS-SSS (symptom severity), pain, bowel dysfunction, and quality of life. [90] [91] [92] The SNRI class of medications is used in the treatment of pain; however, double-blind, placebo-controlled, randomized clinical trials for the relief of IBS, pain, and the associated comorbid depressive or generalized anxiety disorders are required.
Safety. Adverse effects are considerably more common with TCAs, the most frequent of which are drowsiness and dry mouth. Based on population studies, 93, 94 long-term use of some classes of psychotropic drugs for nonpsychiatric indications may be linked to dementia, although a cause-and-effect relationship has not been proven.
Drugs Acting on Opioid Receptors
Mechanism. Opioid receptor agonists slow gut and colonic transit, increase fluid absorption, and reduce the sensation of pain. 95 Efficacy. Loperamide and diphenoxylate, m-opioid agonists, are antidiarrheal agents that have been in use for the treatment of chronic functional diarrhea for many years, 96 based on limited evidence from small studies conducted around 30 years ago. One small trial of 21 patients with IBS-D found that loperamide improved stool consistency, pain, and urgency. 97 A second trial 98 of 60 patients with either functional diarrhea or IBS-D confirmed reduction in stool frequency, improved consistency, and fewer days with pain. A third trial 99 of loperamide in unselected patients with IBS reported improvement in stool frequency and consistency and overall pain intensity but was associated with increased abdominal pain during the night. Loperamide is the most useful agent for diarrhea or urgency. 9 Eluxadoline is a novel k-and m-opioid receptor agonist and d-opioid receptor antagonist. Based on 3 trials with approximately 3000 patients with IBS treated over 12 weeks, it was efficacious in the relief of diarrhea or the composite end point of diarrhea and pain. 100, 101 The recommended dose is 100 mg twice a day unless not tolerated or if there is hepatic impairment, in which case the 75-mg twice a day dose should be used.
Safety. Adverse events with eluxadoline are mainly nausea and headache. Rare cases of pancreatitis and sphincter of Oddi spasm have been reported. In accordance with FDA recommendation, eluxadoline should not be prescribed to patients with a history of biliary obstruction, cholecystectomy, pancreatitis, severe hepatic impairment, or severe constipation or to those who consume more than 3 alcoholic drinks per day.
Off-Label Approaches for Visceral Pain Histamine H 1 Receptor Antagonist Ebastine. Mast cells and their mediators, in particular histamine, seritonin and proteases, contribute to the pathogenesis of IBS. 102 Histamine released by colonic biopsies from patients with IBS can sensitize (via H 1 histamine receptors) the TRP cation channel subfamily V member 1 on neurons in dorsal root ganglia (on afferent pathways) and on human submucosal neurons in rectal biopsies. 103 Ebastine, a nonsedating antagonist of H 1 receptors, has been reported to reduce visceral hypersensitivity, overall IBS symptoms, and abdominal pain in patients with IBS. 103 However, it is not approved for use in the United States at this time.
g-Aminobutyric Acid (GABA)ergic Agents. GABAergic agents are a 2 d ligands that reduce the release of many excitatory neurotransmitters involved in pain mechanisms including glutamate, noradrenaline, substance P, and calcitonin gene-related peptide. Three studies have assessed the effects of gabapentin and pregabalin on rectal and colonic sensation and compliance in patients with IBS-D or healthy controls, and overall the results suggest that these agents reduce senation without significantly affecting compliance. This findings suggests an effect exclusively on sensory mechanisms. [104] [105] [106] A preliminary report of a randomized, controlled, 12-week clinical trial of pregabalin (dose-escalation regimen to a maximum of 225 mg twice a day) conducted at Mayo Clinic, Rochester, Minnesota, in 85 patients with IBS revealed lower average pain scores during weeks 9 through 12 and lower mean IBS-SSS with pregabalin compared with placebo. 107 
Future Approaches to Pain Relief in IBS
A new generation of peripherally active visceral analgesics, 108 including opioid agents with no risk of respiratory depression or addiction potential, is being developed; these medications are eagerly awaited to address the significant unmet need of pain treatment in patients with IBS.
MEDICATIONS FOR DIARRHEA
Opioid agents and antidepressants (TCAs and SNRIs) may relieve diarrhea in addition to their effects on pain (Table) .
5-HT 3 Receptor Antagonists
Mechanism. Of the total body serotonin (5-HT), 90% is found within intestinal enterochromaffin cells. 109, 110 Serotonin is also a transmitter in the brain, and there are several different classes of 5-HT receptors in the brain and gut. Patients with IBS-D have increased and those with IBS-C have reduced postprandial 5-HT levels. 111 The 5-HT 3 receptor antagonists such as alosetron 112 retard colonic transit. The 5-HT 3 receptors are also important mediators of visceral pain. 113 Efficacy. Alosetron is an effective agent based on the results of several meta-analyses of high quality, large RCTs that have all reported consistent results. 114, 115 In these studies, alosetron has an NNT of 8 for relief of abdominal pain and an NNT of 4 for improvement in global symptoms. Alosetron is approved for use in women with severe IBS-D in the United States but is regulated by an FDA prescribing program. Ramosetron is efficacious and licensed for use in both male and female patients with IBS-D in Japan. 116, 117 In a crossover clinical trial 118 in 122 patients with IBS-D, ondansetron had significant effects on stool consistency, urgency, frequency, and bloating but no significant beneficial effect on pain.
Safety. As a drug class, 5-HT 3 antagonists can cause constipation, but it is usually manageable by adjusting the dose. Alosetron, unlike other drugs in this class, is associated with ischemic colitis (w1:800 treated patients). 119 Bile Acid Sequestrants Approximately 25% of patients with IBS-D have evidence of bile acid malabsorption. 120, 121 Although no RCTs of bile acid sequestrants in IBS have been reported, a Mayo Clinic open-label trial of colesevelam, 1875 mg twice daily for 10 days, 122 in patients with IBS-D and increased fecal bile acid excretion documented reduction in stool consistency and frequency. Another open-label study of colestipol, 1 g twice a day for 8 weeks, 123 found improvements in IBS-SSS, stool frequency, and adequate relief of symptoms in patients with IBS-D and bile acid malabsorption (a selenium Se 75 homocholic acid taurine retention <20%).
Antibiotics
Rifaximin is a nonabsorbable antibiotic that has improved global symptoms and bloating in IBS in 2 phase 3 RCTs. 124, 125 These trials included more than 1200 patients with nonconstipated IBS. Rifaximin, 550 mg 3 times a day for 2 weeks, was associated with higher rates of adequate relief of global IBS symptoms and bloating (NNT of 9-12.5). The effect on symptoms lasted up to 10 weeks posttreatment. The NNT of 10 was confirmed for global symptoms and bloating in a metaanalysis of 5 RCTs of rifaximin 126 including 1803 patients. However, stool consistency, frequency of bowel movements, and urgency were not improved.
With repeated courses of rifaximin separated by 10 weeks, 550 mg 3 times a day for 2 weeks in each course, there was significant benefit for urgency, bloating, and combined abdominal pain and stool consistency with each of 2 repeated treatment courses compared with placebo. Rifaximin is approved for patients with IBS-D, with up to 2 repeated treatments in case of symptom recurrence. It is worth noting that rifaximin 127 accelerated ascending colon emptying and overall colonic transit at 48 hours in patients with IBS-D, although it had no effects on intestinal mucosal permeability, stool microbiome, or stool bile acids. The acceleration of colonic transit would seem deleterious for patients with IBS-D; conversely, it may explain the reported improvement in IBS-C (bloating, constipation, and straining) with combined neomycin plus rifaximin compared with neomycin with placebo. 128 Importantly, there is no evidence of adverse effects with rifaximin compared with placebo and no increased risk of Clostridium difficile.
MEDICATIONS FOR CONSTIPATION
Intestinal Secretagogues
Lubiprostone is a prostaglandin derivative that acts on chloride channels on the apical membrane of the intestinal enterocyte to induce chloride secretion, which is then followed by the passive movement of sodium ions and water into the lumen. As a result, stools become looser and gastrointestinal transit is accelerated. 129 The drug is approved at a dose of 8 mg twice daily for women with IBS-C 130 and 24 mg twice daily for men and women with chronic constipation. 131, 132 There are general improvements in abdominal pain scores that parallel the improved straining and stool consistency. Nausea is the most common adverse effect, experienced by 8% of patients, but it is generally relatively mild and self-limited. 133 Linaclotide is a minimally absorbed guanylate cyclase C receptor agonist that causes secretion of chloride and bicarbonate into the intestinal lumen via the cystic fibrosis transmembrane conductance regulator. This results in parallel sodium and water secretion. The activation of cystic fibrosis transmembrane conductance regulator results from increase in intracellular cyclic guanosine monophosphate, which has also been found to affect sensory afferent neurons, leading to inhibition of pain. In clinical trials conducted in patients with IBS-C (as well as others with chronic constipation), linaclotide relieved constipation and significantly improved abdominal discomfort and bloating. [134] [135] [136] Three dose levels are approved: 72, 145, and 290 mg per day: 72-mg and 145-mg doses are for chronic idiopathic constipation, and the 290-mg dose is for IBS-C (in men and women). The dose can be titrated to observe benefit and reduce the risk of diarrhea, which may occur in up to 20% of patients administered the highest dose.
Plecanatide is a peptide analogue of uroguanylin, which is an endogenous guanylate cyclase C receptor agonist 137 released into the intestine from goblet cells. Plecanatide, 3 or 6 mg per day, is also efficacious in treating chronic idiopathic constipation 138 and IBS-C, 139 including relief of worst abdominal pain. Plecanatide, 3-mg dose, is now FDA approved for both indications. It is reported to be associated with lower risk of diarrhea than linaclotide, although the availability of 3 doses of linaclotide provides opportunity to titrate its dose to avoid diarrhea.
5-HT 4 Receptor Agonists
As a class, 5-HT 4 receptor agonists have documented efficacy in patients with IBS-C. Tegaserod (available in come countries but not in the United States) is an effective treatment for IBS-C, relieving overall and multiple individual IBS-C symptoms (abdominal pain/discomfort, bloating, and constipation) in placebocontrolled as well as open-label trials. 140 Repeated treatments with tegaserod are effective, and tegaserod is associated with improvements in quality of life and work productivity. 140 Adverse effects associated with tegaserod are diarrhea, cramping, and rare cardiovascular events, with the lattermost attributed to off-target effects on other 5-HT receptors (eg, 5-HT 2A and 5-HT 2B antagonist). However, in a matched cohort study conducted within a large US health insurance database involving 52,229 patients, there was no increased risk of cardiovascular ischemic events. 141 Mosapride (approved in some countries but not in the United States) improved symptoms in 10 patients with IBS-C in a pilot study. 142 However, a 12-month study in a larger cohort of 69 patients found no significant improvements in overall or specific IBS symptoms (pain, bloating, stool frequency or consistency) or quality of life with mosapride over placebo. 143 Cognitive Behavioral Therapy and Hypnotherapy Where available, cognitive behavioral therapy and hypnotherapy may be used in the management of patients with IBS. Recent systematic reviews have found that psychological interventions are efficacious, including longterm benefits, and that the gains are not dependent on the number of sessions. Indeed, cognitive behavioral therapy and hypnosis appear efficacious in minimal-contact formats as well as various technologies (eg, Internet, telephone, smartphone apps), self-help interventions, and engaging trained nonprofessional mental health professionals to deliver interventions. 144 
CONCLUSION
Currently, the treatment of IBS remains focused on treating the patient's most troublesome symptom. These treatments are quite efficacious for bowel dysfunction, although the treatment of pain without use of opioids or centrally acting agents is suboptimal. Hence, lifestyle interventions including diet, cognitive behavioral therapy and hypnotherapy (the lattermost not discussed here) should be considered to relieve symptoms in a holistic approach to the patient's symptoms. Pharmacotherapies have not been proved to alter the long-term or natural history of the disorder. There is still considerable unmet needdnew treatments that target some of the important actionable biomarkers of IBS, as well as the ability to conduct high-quality, randomized, controlled trials, augur well for the development of treatments that will impact patients' symptoms and hopefully the natural history of IBS in the future. In particular, the new generation of peripherally active visceral analgesics, including opioid agents with no risk of respiratory depression or addiction potential, is eagerly awaited to address the significant unmet need of pain in IBS.
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